CD8A and neoplasm: In addition, there was a higher frequency of DCs in the tumor-draining lymph nodes (0.20% ± 0.02% in anti–PD-1 plus mTAK-500–treated animals vs. 0.15% ± 0.02% in mTAK-500–treated animals; Fig. 5B) with comparable CD8+ T-cell activation relative to controls (Fig. 5B).